Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
Background: The pharmacokinetics and pharmacodynamics of a novel orally disintegrating tablet (ODT) formulation of delayed-release dexlansoprazole 30 mg was evaluated versus the dexlansoprazole 30 mg capsule in this phase I, open-label, multiple-dose, randomized, two-period crossover study. Methods:...
Main Authors: | Michael Kukulka, Sai Nudurupati, Maria Claudia Perez |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-11-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756283X16670073 |
Similar Items
-
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
by: Michael Kukulka, et al.
Published: (2016-11-01) -
Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
by: Kukulka M, et al.
Published: (2014-12-01) -
Formulation and evaluation of orally disintegrating clopidogrel tablets
by: Gamal Mohamed Mahrous, et al. -
Formulation and development of paediatric orally disintegrating carbamazepine tablets
by: R Canadell-Heredia, et al.
Published: (2022-11-01) -
Formulation and in vitro Evaluations of Paracetamol Orally Disintegrating Tablets
by: Azmiera Azimuddin, et al.
Published: (2023-03-01)